利伐沙班 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "利伐沙班" in Chinese language version.

refsWebsite

Global rank Chinese rank

31web.archive.org

1^st place

18doi.org

2^nd place

23^rd place

18nih.gov

4^th place

5^th place

5fda.gov

447^th place

581^st place

4drugs.com

399^th place

208^th place

2handle.net

102^nd place

492^nd place

2clincalc.com

3,912^th place

5,917^th place

2semanticscholar.org

11^th place

332^nd place

2rxlist.com

7,927^th place

5,088^th place

2drugnews.net

low place

2europa.eu

68^th place

209^th place

1xarelto.com

low place

1books.google.com

3^rd place

8^th place

1bloomberg.com

99^th place

225^th place

1nice.org.uk

3,258^th place

2,433^rd place

1webmd.com

1,169^th place

1,094^th place

1uzh.ch

3,633^rd place

low place

1globenewswire.com

2,614^th place

6,491^st place

1reuters.com

49^th place

81^st place

1bayer.com

low place

1fiercebiotech.com

low place

1bionity.com

low place

1washingtonpost.com

34^th place

129^th place

1nytimes.com

7^th place

31^st place

1dukechronicle.com

low place

1ed.ac.uk

1,871^st place

2,278^th place

bayer.com

press.bayer.com

Bayer comments on article in The British Medical Journal (BMJ) regarding Xarelto (PDF). Bayer AG Communications, Government Relations & Corporate Brand. September 29, 2016 [2022-09-20]. （原始内容存档 (PDF)于2017-01-31）.

bionity.com

Bayer's Novel Anticoagulant Xarelto now also approved in the EU (新闻稿). Bayer. February 10, 2008 [January 31, 2010]. （原始内容存档于2008-10-22）.

bloomberg.com

Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug. April 22, 2019 [April 24, 2019]. （原始内容存档于2019-08-01）.

books.google.com

Kiser K. Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. 2017: 11. ISBN 9783319546438.

clincalc.com

The Top 300 of 2019. ClinCalc. [October 16, 2021]. （原始内容存档于2020-03-18）.
Rivaroxaban - Drug Usage Statistics. ClinCalc. [October 16, 2021]. （原始内容存档于2020-07-08）.

doi.org

dx.doi.org

Fassiadis N. Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opinion on Pharmacotherapy. December 2009, 10 (18): 2945–2946. PMID 19925048. S2CID 23498967. doi:10.1517/14656560903413559.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Annals of Internal Medicine. December 2018, 169 (11): 774–787. PMC 6825839 . PMID 30383133. doi:10.7326/M18-1523.
Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013, 2013: 640723. PMC 3885278 . PMID 24455237. doi:10.1155/2013/640723 .
Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. Journal of the American Academy of Dermatology. March 2015, 72 (3): 524–34. PMID 25486915. doi:10.1016/j.jaad.2014.10.027.
Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, Reddy M. Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. Health Services Insights. 2016, 9 (Suppl 1): 25–36. PMC 5156547 . PMID 28008269. doi:10.4137/HSI.S40701.
Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British Journal of Clinical Pharmacology. September 2013, 76 (3): 455–66. PMC 3769672 . PMID 23305158. doi:10.1111/bcp.12075.
Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology. August 2015, 80 (2): 285–93. PMC 4541976 . PMID 25689417. doi:10.1111/bcp.12611.
Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury (PDF). Journal of Hepatology. August 2014, 61 (2): 293–300 [2022-09-20]. PMID 24681117. doi:10.1016/j.jhep.2014.03.026. （原始内容存档 (PDF)于2018-12-11）.
Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. February 2015, 35 (2): 198–207. PMID 25644580. S2CID 22593448. doi:10.1002/phar.1532.
Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. Journal of Medicinal Chemistry. September 2005, 48 (19): 5900–8. PMID 16161994. doi:10.1021/jm050101d.
Ansell J. Outpatient Oral Anticoagulant Therapy. Consultative Hemostasis and Thrombosis Fourth. Elsevier. January 2019: 747–777. ISBN 978-0-323-46202-0. doi:10.1016/B978-0-323-46202-0.00037-6.
Turpie AG. New oral anticoagulants in atrial fibrillation. European Heart Journal. January 2008, 29 (2): 155–65. PMID 18096568. doi:10.1093/eurheartj/ehm575 .
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. November 2006, 114 (22): 2374–2381. PMID 17116766. doi:10.1161/CIRCULATIONAHA.106.642074 .
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. November 2006, 114 (22): 2374–2381. PMID 17116766. doi:10.1161/CIRCULATIONAHA.106.642074 .
Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. International Journal of Clinical Pharmacology and Therapeutics. July 2013, 51 (7): 549–561. PMID 23458226. doi:10.5414/CP201812.
Singh AK, Noronha V, Gupta A, Singh D, Singh P, Singh A, Singh A. Rivaroxaban: Drug review. Cancer Res Stat Treat. 2020, 3: 264–269. doi:10.4103/CRST.CRST_122_19.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine. September 2011, 365 (10): 883–91. PMC 3860773 . PMID 21830957. doi:10.1056/NEJMoa1009638.
Patel MR, Hellkamp AS, Fox KA. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial (PDF). The New England Journal of Medicine. February 2016, 374 (8): 785–8 [2022-09-20]. PMID 26839968. doi:10.1056/NEJMc1515842. hdl:20.500.11820/69b742f0-5b6d-4f54-93a5-98a1da909653 . （原始内容存档 (PDF)于2018-07-22）.

drugnews.net

Schroeder C. ISMP Ranks Xarelto Most Dangerous Drug in the United States. DrugNews. DrugNews. [August 10, 2016]. （原始内容存档于2016-08-11）.
Schroeder C. Possible Antidote Could Help Blood Thinner Patients In Bleeding Emergencies. DrugNews. [August 20, 2015]. （原始内容存档于2015-05-10）.

drugs.com

Rivaroxaban Use During Pregnancy. Drugs.com. [March 3, 2019]. （原始内容存档于2019-03-27）.
Rivaroxaban Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [March 3, 2019]. （原始内容存档于2019-03-27）.
Generic Xarelto Availability. Drugs.com. [May 9, 2017]. （原始内容存档于2018-06-16）.
Xarelto FDA Approval History. 7 September 2020 [2022-09-20]. （原始内容存档于2022-09-22）.

dukechronicle.com

Patel V. Duke clinical trial under scrutiny in drug case. The Chronicle. Duke Student Publishing Company. [2022-09-20]. （原始内容存档于2016-05-08）.

ed.ac.uk

pure.ed.ac.uk

Patel MR, Hellkamp AS, Fox KA. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial (PDF). The New England Journal of Medicine. February 2016, 374 (8): 785–8 [2022-09-20]. PMID 26839968. doi:10.1056/NEJMc1515842. hdl:20.500.11820/69b742f0-5b6d-4f54-93a5-98a1da909653 . （原始内容存档 (PDF)于2018-07-22）.

europa.eu

ema.europa.eu

Xarelto EPAR. European Medicines Agency (EMA). [November 13, 2020]. （原始内容存档于2023-01-27）.

emea.europa.eu

European Medicines Agency. CHP Assessment Report for Xarelto (EMEA/543519/2008) (PDF). 2008 [June 11, 2009]. ^{[永久失效連結]}

fda.gov

Medication Guide – Xarelto (PDF). U.S. Food and Drug Administration. [September 1, 2014]. （原始内容存档 (PDF)于2014-05-02）.
Accelerated Approval for AndexXa (PDF). FDA. [August 1, 2018]. （原始内容存档 (PDF)于2018-07-26）.
FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. US Food and Drug Association. November 4, 2011 [April 27, 2016]. （原始内容存档于2011-11-05）.
Meet Robert M. Califf, M.D., Commissioner of Food and Drugs. U.S. Food and Drug Administration. U.S. Food and Drug Administration. [May 3, 2016]. （原始内容存档于2016-05-15）.

accessdata.fda.gov

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. www.accessdata.fda.gov. [April 24, 2019]. （原始内容存档于2020-09-13）.

fiercebiotech.com

Bayer's Xarelto Approved in Canada (新闻稿). Bayer. September 16, 2008 [January 31, 2010]. （原始内容存档于2011-07-11）.

globenewswire.com

U.S. FDA Approves Portola Pharmaceuticals' Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors. Portola Pharmaceuticals Inc. (GlobeNewswire News Room). [August 1, 2018]. （原始内容存档于2021-04-10）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.
Patel MR, Hellkamp AS, Fox KA. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial (PDF). The New England Journal of Medicine. February 2016, 374 (8): 785–8 [2022-09-20]. PMID 26839968. doi:10.1056/NEJMc1515842. hdl:20.500.11820/69b742f0-5b6d-4f54-93a5-98a1da909653 . （原始内容存档 (PDF)于2018-07-22）.

nice.org.uk

Overview | Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | Guidance | NICE. www.nice.org.uk. [January 1, 2020]. （原始内容存档于2020-05-13）.

nih.gov

ncbi.nlm.nih.gov

Abdulsattar Y, Bhambri R, Nogid A. Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor. P & T. May 2009, 34 (5): 238–44. PMC 2697099 . PMID 19561868.
Fassiadis N. Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opinion on Pharmacotherapy. December 2009, 10 (18): 2945–2946. PMID 19925048. S2CID 23498967. doi:10.1517/14656560903413559.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Annals of Internal Medicine. December 2018, 169 (11): 774–787. PMC 6825839 . PMID 30383133. doi:10.7326/M18-1523.
Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013, 2013: 640723. PMC 3885278 . PMID 24455237. doi:10.1155/2013/640723 .
Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. Journal of the American Academy of Dermatology. March 2015, 72 (3): 524–34. PMID 25486915. doi:10.1016/j.jaad.2014.10.027.
Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, Reddy M. Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. Health Services Insights. 2016, 9 (Suppl 1): 25–36. PMC 5156547 . PMID 28008269. doi:10.4137/HSI.S40701.
Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British Journal of Clinical Pharmacology. September 2013, 76 (3): 455–66. PMC 3769672 . PMID 23305158. doi:10.1111/bcp.12075.
Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology. August 2015, 80 (2): 285–93. PMC 4541976 . PMID 25689417. doi:10.1111/bcp.12611.
Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury (PDF). Journal of Hepatology. August 2014, 61 (2): 293–300 [2022-09-20]. PMID 24681117. doi:10.1016/j.jhep.2014.03.026. （原始内容存档 (PDF)于2018-12-11）.
Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. February 2015, 35 (2): 198–207. PMID 25644580. S2CID 22593448. doi:10.1002/phar.1532.
Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. Journal of Medicinal Chemistry. September 2005, 48 (19): 5900–8. PMID 16161994. doi:10.1021/jm050101d.
Turpie AG. New oral anticoagulants in atrial fibrillation. European Heart Journal. January 2008, 29 (2): 155–65. PMID 18096568. doi:10.1093/eurheartj/ehm575 .
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. November 2006, 114 (22): 2374–2381. PMID 17116766. doi:10.1161/CIRCULATIONAHA.106.642074 .
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. November 2006, 114 (22): 2374–2381. PMID 17116766. doi:10.1161/CIRCULATIONAHA.106.642074 .
Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. International Journal of Clinical Pharmacology and Therapeutics. July 2013, 51 (7): 549–561. PMID 23458226. doi:10.5414/CP201812.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine. September 2011, 365 (10): 883–91. PMC 3860773 . PMID 21830957. doi:10.1056/NEJMoa1009638.
Patel MR, Hellkamp AS, Fox KA. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial (PDF). The New England Journal of Medicine. February 2016, 374 (8): 785–8 [2022-09-20]. PMID 26839968. doi:10.1056/NEJMc1515842. hdl:20.500.11820/69b742f0-5b6d-4f54-93a5-98a1da909653 . （原始内容存档 (PDF)于2018-07-22）.

dailymed.nlm.nih.gov

Xarelto- rivaroxaban tablet, film coated Xarelto- rivaroxaban tablet, film coated Xarelto- rivaroxaban kit. DailyMed. [November 13, 2020]. （原始内容存档于2021-04-19）.

nytimes.com

Thomas K. Document Claims Drug Makers Deceived a Top Medical Journal. The New York Times. March 1, 2016 [May 3, 2016]. （原始内容存档于2016-03-05）.

reuters.com

Berkrot B. New blood thinner 'antidote' to help doctors move past warfarin. Reuters. December 23, 2015 [2022-09-20]. （原始内容存档于2019-04-03）.

rxlist.com

Xarelto Side Effects Center. RxList. [September 1, 2014]. （原始内容存档于2014-09-03）.
Xarelto Side Effects Center. RxList. [September 1, 2014]. （原始内容存档于2014-09-03）.

semanticscholar.org

api.semanticscholar.org

Fassiadis N. Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opinion on Pharmacotherapy. December 2009, 10 (18): 2945–2946. PMID 19925048. S2CID 23498967. doi:10.1517/14656560903413559.
Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. February 2015, 35 (2): 198–207. PMID 25644580. S2CID 22593448. doi:10.1002/phar.1532.

uzh.ch

zora.uzh.ch

Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury (PDF). Journal of Hepatology. August 2014, 61 (2): 293–300 [2022-09-20]. PMID 24681117. doi:10.1016/j.jhep.2014.03.026. （原始内容存档 (PDF)于2018-12-11）.

washingtonpost.com

Bayer, Johnson & Johnson settle more than 25,000 lawsuits over blood thinner Xarelto for $775 million. washingtonpost.com. [April 7, 2019]. （原始内容存档于2019-03-26）.

web.archive.org

Rivaroxaban Use During Pregnancy. Drugs.com. [March 3, 2019]. （原始内容存档于2019-03-27）.
Xarelto- rivaroxaban tablet, film coated Xarelto- rivaroxaban tablet, film coated Xarelto- rivaroxaban kit. DailyMed. [November 13, 2020]. （原始内容存档于2021-04-19）.
Xarelto EPAR. European Medicines Agency (EMA). [November 13, 2020]. （原始内容存档于2023-01-27）.
Xarelto: Summary of Product Characteristics. Bayer Schering Pharma AG. 2008 [February 11, 2009]. （原始内容存档于2010-07-27）.
Rivaroxaban Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [March 3, 2019]. （原始内容存档于2019-03-27）.
Generic Xarelto Availability. Drugs.com. [May 9, 2017]. （原始内容存档于2018-06-16）.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. www.accessdata.fda.gov. [April 24, 2019]. （原始内容存档于2020-09-13）.
Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug. April 22, 2019 [April 24, 2019]. （原始内容存档于2019-08-01）.
The Top 300 of 2019. ClinCalc. [October 16, 2021]. （原始内容存档于2020-03-18）.
Rivaroxaban - Drug Usage Statistics. ClinCalc. [October 16, 2021]. （原始内容存档于2020-07-08）.
Xarelto FDA Approval History. 7 September 2020 [2022-09-20]. （原始内容存档于2022-09-22）.
Overview | Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | Guidance | NICE. www.nice.org.uk. [January 1, 2020]. （原始内容存档于2020-05-13）.
Medication Guide – Xarelto (PDF). U.S. Food and Drug Administration. [September 1, 2014]. （原始内容存档 (PDF)于2014-05-02）.
Xarelto Side Effects. WebMD. [September 1, 2014]. （原始内容存档于2014-09-03）.
Xarelto Side Effects Center. RxList. [September 1, 2014]. （原始内容存档于2014-09-03）.
Xarelto Side Effects Center. RxList. [September 1, 2014]. （原始内容存档于2014-09-03）.
Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury (PDF). Journal of Hepatology. August 2014, 61 (2): 293–300 [2022-09-20]. PMID 24681117. doi:10.1016/j.jhep.2014.03.026. （原始内容存档 (PDF)于2018-12-11）.
Schroeder C. ISMP Ranks Xarelto Most Dangerous Drug in the United States. DrugNews. DrugNews. [August 10, 2016]. （原始内容存档于2016-08-11）.
Schroeder C. Possible Antidote Could Help Blood Thinner Patients In Bleeding Emergencies. DrugNews. [August 20, 2015]. （原始内容存档于2015-05-10）.
Accelerated Approval for AndexXa (PDF). FDA. [August 1, 2018]. （原始内容存档 (PDF)于2018-07-26）.
U.S. FDA Approves Portola Pharmaceuticals' Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors. Portola Pharmaceuticals Inc. (GlobeNewswire News Room). [August 1, 2018]. （原始内容存档于2021-04-10）.
Berkrot B. New blood thinner 'antidote' to help doctors move past warfarin. Reuters. December 23, 2015 [2022-09-20]. （原始内容存档于2019-04-03）.
Bayer comments on article in The British Medical Journal (BMJ) regarding Xarelto (PDF). Bayer AG Communications, Government Relations & Corporate Brand. September 29, 2016 [2022-09-20]. （原始内容存档 (PDF)于2017-01-31）.
Bayer's Xarelto Approved in Canada (新闻稿). Bayer. September 16, 2008 [January 31, 2010]. （原始内容存档于2011-07-11）.
Bayer's Novel Anticoagulant Xarelto now also approved in the EU (新闻稿). Bayer. February 10, 2008 [January 31, 2010]. （原始内容存档于2008-10-22）.
FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. US Food and Drug Association. November 4, 2011 [April 27, 2016]. （原始内容存档于2011-11-05）.
Bayer, Johnson & Johnson settle more than 25,000 lawsuits over blood thinner Xarelto for $775 million. washingtonpost.com. [April 7, 2019]. （原始内容存档于2019-03-26）.
Thomas K. Document Claims Drug Makers Deceived a Top Medical Journal. The New York Times. March 1, 2016 [May 3, 2016]. （原始内容存档于2016-03-05）.
Patel V. Duke clinical trial under scrutiny in drug case. The Chronicle. Duke Student Publishing Company. [2022-09-20]. （原始内容存档于2016-05-08）.
Meet Robert M. Califf, M.D., Commissioner of Food and Drugs. U.S. Food and Drug Administration. U.S. Food and Drug Administration. [May 3, 2016]. （原始内容存档于2016-05-15）.
Patel MR, Hellkamp AS, Fox KA. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial (PDF). The New England Journal of Medicine. February 2016, 374 (8): 785–8 [2022-09-20]. PMID 26839968. doi:10.1056/NEJMc1515842. hdl:20.500.11820/69b742f0-5b6d-4f54-93a5-98a1da909653 . （原始内容存档 (PDF)于2018-07-22）.

webmd.com

Xarelto Side Effects. WebMD. [September 1, 2014]. （原始内容存档于2014-09-03）.

xarelto.com

Xarelto: Summary of Product Characteristics. Bayer Schering Pharma AG. 2008 [February 11, 2009]. （原始内容存档于2010-07-27）.